Cornell researchers have developed a new vaccine platform that could provide more robust, longer-lasting protection from both COVID-19 and influenza, and broader immunity to different flu strains.

Hemagglutinin is a receptor-binding and membrane fusion glycoprotein—it is produced by viruses to allow them to bind to receptors in a host. The researchers found, unsurprisingly, that ...

Brass et al. 1 used fluorescence microscopy to score the abundance of the influenza envelope glycoprotein hemagglutinin as a marker of infection with influenza A/PR/8/34 (PR8) virus in siRNA ...